Journal Mobile Options
Table of Contents
Vol. 72, No. 4, 2005
Issue release date: 2005
Digestion 2005;72:212–218

Use of Proton Pump Inhibitors: An Exploration of the Attitudes, Knowledge and Perceptions of General Practitioners

Raghunath A.S. · Hungin A.P.S. · Cornford C.S. · Featherstone V.
aSchool for Health, University of Durham, Queen’s Campus, Wolfson Research Institute, Stockton-on-Tees, and b Wold Research Network, Hull and East Yorkshire, Hull, UK

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background/Aim: Proton pump inhibitor (PPI) prescribing is costly. The volume of PPI prescription is also increasing, despite little evidence that would justify the increase. General practitioners (GPs) are largely responsible for PPI prescribing, yet knowledge of their views concerning PPIs which might explain the apparent anomaly of prescribing costly drugs without justification is lacking. The aim of this study is therefore to investigate how GPs make decisions about PPI prescribing. Method: Qualitative study design using focus groups of 34 GPs and 15 training GPs analysed according to grounded theory principles and use of constant comparative analysis. Results:The participants showed agreement about the clinical factors potentially relevant to PPI prescribing such as age of presentation and endoscopy, issues of Helicobacter pylori eradication and issues around malignancy. There was considerable controversy, however, as to how to apply those factors in real clinical consultations. GPs in training and academic GPs tended to be more conservative; service-based GPs more pragmatic. There was agreement about the need to review long-term PPI medication, but controversy about whether the conventional ‘step-up step-down’ approach was realistic in practice. Good agreement was apparent about the effectiveness, the cost implications, and some of the ethical issues surrounding PPIs, but considerable controversy as to how far such factors should influence prescribing of PPIs. Conclusion:The GPs showed good understanding and knowledge of the issues surrounding PPI prescribing. There was considerable controversy as to how such knowledge should be translated into practice.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Department of Health: Prescription Cost Analysis: England 2002. London, Department of Health, 2003.
  2. Hungin AP, Rubin GP, O’Flanagan H: Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 1999;49:451–453.
  3. Shaheen N, Ransohoff DF: Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: clinical applications. JAMA 2002;287:1982–1986.
  4. Lagergren J, Bergstrom R, Lindgren A, Nyren O: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825–831.
  5. Dent J, Jones R, Kahrilas P, Talley NJ: Management of gastro-oesophageal reflux disease in general practice. BMJ 2001;322:344–347.
  6. National Institute for Clinical Excellence: Technology Appraisal No.7: Guidance on the Use of Proton Pump Inhibitors in the Treatment of Dyspepsia. London, NICE, 2000.
  7. Boath EH, Blenkinsopp A: The rise and rise of proton pump inhibitor drugs: patients’ perspectives. Soc Sci Med 1997;45:1571–1579.
  8. Barbour RS: Using focus groups in general practice research. Fam Pract 1995;12:328–334.
  9. Glaser BG, Strauss AL: The purpose and credibility of qualitative research. Nurs Res 1966;15:56–61.
  10. Green J: Grounded theory and the constant comparative method. BMJ 1998;316:1064–1065.
  11. QSR NUD*IST 4 and NUD*IST Vivo Software for Qualitative Data Analysis. Google Search: QSR.NUD.IST, 2005.
  12. Carthy P, Harvey I, Brawn R, Watkins C: A study of factors associated with cost and variation in prescribing among GPs. Fam Pract 2000;17:36–41.
  13. Mazza D, Russell SJ: Are GPs using clinical practice guidelines? Aust Fam Physician 2001;30:817–821.
  14. Raghunath AS, Hungin APS: Long-term prescribing of proton pump inhibitors in primary care: a cross-sectional survey (abstract). Gut 2004;53(suppl 111):24.
  15. Wang WH, Huang JQ, Zheng GF, Xia HH, Wong WM, Lam SK, et al: Head-to-head comparison of H(2)-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol 2005;11:4067–4077.
  16. van Pinxteren B, Numans ME, Bonis PA, Lau J: Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2001; CD002095.
  17. Hatlebakk JG, Hyggen A, Madsen PH, Walle PO, Schulz T, Mowinckel P, et al: Heartburn treatment in primary care: randomised, double blind study for 8 weeks. BMJ 1999;319:550–553.
  18. Donnellan C, Sharma N, Preston C, Moayyedi P: Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2005;CD003245.
  19. NICE Guideline: Dyspepsia: Managing Dyspepsia in Adults in Primary Care. National Guideline Research and Development Unit, University of Newcastle upon Tyne, 2004.
  20. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al: Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002;CD002296.
  21. Gill D, Sharpe M: Frequent consulters in general practice: a systematic review of studies of prevalence, associations and outcome. J Psychosom Res 1999;47:115–130.
  22. Vedsted P, Fink P, Sorensen HT, Olesen F: Physical, mental and social factors associated with frequent attendance in Danish general practice. A population-based cross-sectional study. Soc Sci Med 2004;59:813–823.
  23. Grime J, Pollock K, Blenkinsopp A: Proton pump inhibitors: perspectives of patients and their GPs. Br J Gen Pract 2001;51:703–711.
  24. Chan J, Hui RL, Szpakowski JL: Prescribing proton pump inhibitors for initial treatment of acid-related gastrointestinal diseases in a managed care population. Am J Manag Care 2004;10:433–441.

    External Resources

  25. Eggleston A, Wigerinck A, Huijghebaert S, Dubois D, Haycox A: Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: a clinical database analysis. Gut 1998;42:13–16.
  26. Inadomi JM, McIntyre L, Bernard L, Fendrick AM: Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003;98:1940–1944.
  27. Mine S, Iida T, Tabata T, Kishikawa H, Tanaka Y: Management of symptoms in step-down therapy of gastroesophageal reflux disease. J Gastroenterol Hepatol 2005;20:1365–1370.
  28. Galmiche JP, Letessier E, Scarpignato C: Treatment of gastro-oesophageal reflux disease in adults. BMJ 1998;316:1720–1723.
  29. Vakil N: How valuable are proton-pump inhibitors in establishing a diagnosis of gastro-oesophageal reflux disease? Aliment Pharmacol Ther 2005;22(suppl 1):64–69.
  30. Malfertheiner P, Megraud F, O’Morain C, Hungin APS, Jones R, Axon A, et al: Current concepts in the management of Helicobacter pylori infection – the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167–180.
  31. Raghunath AS, Hungin AP, Childs S, Wooff D: The prevalence of Helicobacter pylori in gastro-oesophageal reflux disease: a systematic review. BMJ 2003;326:736–739.

    External Resources

  32. Raghunath AS, Hungin AP, Wooff D, Childs S: Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Aliment Pharmacol Ther 2004;20:733–744.
  33. Wathen B, Dean T: An evaluation of the impact of NICE guidance on GP prescribing. Br J Gen Pract 2004;54:103–107.
  34. Pollock K, Grime J: The cost and cost-effectiveness of PPIs – GP perspectives and responses to a prescribing dilemma and their implications for the development of patient- centred healthcare. Eur J Gen Pract 2003;9:126–133, 140.
  35. Delaney BC, Moayyedi P, Forman D: Initial management strategies for dyspepsia. Cochrane Database Syst Rev, 2003.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50